News | June 02, 2008

GE Focuses on PET-VCAR Innovations at ASCO

June 3, 2008 – GE showcased at ASCO its latest advances in molecular imaging technologies such as the IN Cell Analyzer, Positron Emission Tomography/Volume Computer Assisted Reading (PET-VCAR) and Fastlab automated PET radiopharmacy, aiming to help healthcare providers understand the molecular root of diseases and explore new paths for detecting, treating and monitoring illnesses earlier.

PET-VCAR is a complement to GE’s approach to personal patient management. The system reportedly helps optimize tumor management by enabling early quantification and evaluation of treatment effectiveness, a valuable tool for treatment planning. It features workflow enhancements for both single and multi-exam review, and includes exam-to-exam auto-registration; tumor segmentation and quantification; and multiplanar image review.

IN Cell Analyzer System from GE’s Life Science Division, represents a complete solution for high-content sub-cellular analysis. Used in research and drug discovery, the system performs assays directly inside cells and uses image analysis techniques to give quantitative results for those assays for each individual cell. The power of the IN Cell Analyzer comes from using the high throughput it delivers to analyze thousands of cells under different conditions to generate statistically robust data.

Fastlab is the first multitracer PET chemistry synthesis platform to feature a cassette that incorporates premeasured, preloaded reagents—an innovation that reportedly delivers higher yields, improved reproducibility and faster synthesis than any other platform. It is designed to accommodate different chemistries, facilitating the production of multiple PET tracers. The first application launched on the platform is FDG. GE Healthcare is planning to expand the utility of the platform by developing a range of other radiopharmaceuticals, including GE Healthcare proprietary diagnostic imaging agents.

The GE Signa Vibrant is a dedicated 1.5T breast MR scanner utilizing High Definition technology and applications specifically designed for breast MR, including: VIBRANT acquisition, BREASE spectroscopy, integrated CADstream (manufactured by Confirma) and a specially designed breast MR patient table designed to provide optimal imaging and outstanding access for intervention. Signa Vibrant’s design is said to be ideally suited for the environment of many breast-imaging centers.

GE helps physicians take aim at cancer with their Advanced Imaging technologies for radiation therapy planning. GE’s radiation therapy solutions include advanced imaging technologies with LightSpeedRT16 wide-bore multislice CT simulator, Discovery PET-CT scanner, Signa MR system and radiation oncology simulation software, providing tools geared at maximizing the potential of new treatment delivery technologies.

GE also showcased solutions from its Centricity portfolio, including the Centricity Electronic Medical Record, Practice Solution and PACS. With users reportedly ranging from the nation’s largest healthcare organization to the solo practitioner, the Centricity EMR is an ambulatory system relied on by more than 30,000 clinicians nationwide. Centricity Practice Solution is a completely integrated clinical and financial management solution aimed to provide a singular approach to a more efficient, high quality practice – extending from the patient’s first visit to final reimbursement.

For more information:

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...